Essential thrombocythemia is a type of myeloproliferative disorder that is benign and has a slow growth rate . Essential thrombocythemia, or ET for short, is a clonal disease of hematopoietic stem cells in which the peripheral blood platelet count is markedly elevated and functionally abnormal. In the early stages of ET, there may be no clinical symptoms, and the disease may be detected only incidentally during a blood count. Bleeding or thrombosis is the main clinical manifestation, and there may be fatigue and splenomegaly. Clinically, low-risk asymptomatic patients <60 years of age without cardiovascular disease do not require treatment, while high-risk patients >60 years of age and/or with a history of cardiovascular disease require aggressive treatment. Primary platelets progress slowly, and those with recurrent bleeding or thrombosis have a poorer prognosis. Patients are advised to go to the hematology department of a regular regulated hospital for treatment to avoid delays.